Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
19.01
-0.28 (-1.45%)
At close: Apr 28, 2026, 4:00 PM EDT
19.01
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Monte Rosa Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Monte Rosa Therapeutics stock have an average target of 32, with a low estimate of 29 and a high estimate of 37. The average target predicts an increase of 68.33% from the current stock price of 19.01.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 18, 2026.
Analyst Ratings
The average analyst rating for Monte Rosa Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Buy | 1 | 2 | 3 | 3 | 3 | 2 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $34 → $30 | Strong Buy | Maintains | $34 → $30 | +57.81% | Mar 18, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $30 → $29 | Buy | Maintains | $30 → $29 | +52.55% | Mar 18, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $28 → $37 | Buy | Reiterates | $28 → $37 | +94.63% | Jan 14, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $22 → $30 | Buy | Maintains | $22 → $30 | +57.81% | Jan 8, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $16 → $34 | Strong Buy | Maintains | $16 → $34 | +78.85% | Jan 8, 2026 |
Financial Forecast
Revenue This Year
57.90M
from 123.67M
Decreased by -53.18%
Revenue Next Year
59.32M
from 57.90M
Increased by 2.45%
EPS This Year
-1.68
from -0.46
EPS Next Year
-1.77
from -1.68
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 200.6M | 300.3M | ||||||
| Avg | 57.9M | 59.3M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 62.2% | 418.6% | ||||||
| Avg | -53.2% | 2.4% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | -1.04 | 0.61 | ||||
| Avg | -1.68 | -1.77 | ||||
| Low | -2.13 | -2.82 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.